Cingulate Inc. (CING) vs RenovoRx, Inc. (RNXT)

A side-by-side comparison of Cingulate Inc. and RenovoRx, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

CING

Cingulate Inc.

$66M

$4.90HealthcareDelayed quote: Oct 6, 2026, 1:49 PM EDT

RNXT

RenovoRx, Inc.

$64M

$1.43HealthcareDelayed quote: Oct 6, 2026, 1:50 PM EDT

Total return — CING vs RNXT

growth of $100 · dividends reinvested · last 5y

CING -99.6% (-66.1%/yr)RNXT -75.8% (-24.7%/yr)RNXT compounded faster over this window

Log scale — wide-divergence pair

CING RNXT

CING vs RNXT: by the numbers

•CING is the larger company ($66M vs $64M market cap).
•Both run net losses; CING's is the smaller (0.00% vs -621.71% net margin).

Metrics side by side

Valuation

Metric	CING	RNXT
P/S ratio	N/A	32.49
P/B ratio	2.81	7.15
EV / EBITDA	0.23	N/A

Profitability

Metric	CING	RNXT
Gross margin	0.00%	70.88%
Operating margin	0.00%	-1113.98%
Net margin	0.00%	-621.71%
ROE	-122.71%	-136.82%
ROIC	-83.74%	-139.74%

Growth (annualized)

Metric	CING	RNXT
Total return CAGR (5Y)	N/A	-23.80%

Go deeper

Full CING analysis Full RNXT analysis Interactive comparison tool

Dig into the metrics

Cingulate ROE RenovoRx ROE Cingulate operating margin RenovoRx operating margin Cingulate revenue growth RenovoRx revenue growth Cingulate free cash flow RenovoRx free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.